- 期刊
Gefitinib產生抗藥性後轉換 Erlotinib治療之案例報告及文獻回顧
Erlotinib after Gefitinib Failure in Patients with Advanced Non-Small Cell Lung Cancer -- A Case Report and Review of the Literature
並列摘要
Gefitinib and Erlotinib both are the first-generation oral epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), which have excellent antitumor effects against advanced or recurrent non-small cell lung cancer (NSCLC). Despite initially showing a good response, most patients present with recurrence of the disease; this is due to the development of resistance to EGFR-TKIs. Since the lack of a standard therapeutic option for NSCLC patients who have progressive disease after EGFRTKIs failure, this article discussed the subsequent treatment choices for patients with acquired resistance to gefitinib by an EGFR mutation with advanced adenocarcinoma male patient.
延伸閱讀
- Chen, K. C., Chang, G. C., Yang, T. T., Kuo, B. I. T., Lin, C. P., & Hsu, J. Y. (2004). 比較Gefitinib與Cisplatin和Gemcitabine合併治療用於未經治療的晚期非小細胞肺癌之差異－病例對照研究. 胸腔醫學, 19(5), 340-345. https://doi.org/10.29806/TM.200410.0004
- 謝媛喬（2003）。Repaglinide（NovoNorm）與gemfibrozil（Lopid）之藥物交互作用。嘉基藥訊，(48)，1-4。https://doi.org/10.30148/JJYS.200311.0001
- 施維宜（2008）。使用gefitinib或化學治療對末期非小細胞肺癌病患的醫療費用及成本效果分析〔碩士論文，國立臺灣大學〕。華藝線上圖書館。https://doi.org/10.6342/NTU.2008.02583
- 周立婷（2022）。比較upadacitinib與新機轉藥物在乾癬性關節炎患者之療效及安全性：系統性文獻回顧及網絡統合分析〔碩士論文，國立臺灣大學〕。華藝線上圖書館。https://doi.org/10.6342/NTU202204022
- Yano, Y., Namba, Y., Mori, M., Nakazawa, Y., Nashi, A., Kagami, S., Niinaka, M., Yoneda, T., Kimura, H., Yamaguchi, T., & Yokota, S. (2012). Treatment of Non-Small-Cell Lung Cancer with Erlotinib following Gefitinib-Induced Hepatotoxicity: Review of 8 Clinical Cases. Lung Cancer International, 2012(), 2-7. https://doi.org/10.1155/2012/354657